Type 1 Diabetes Market Report Scope & Overview:

The Type 1 Diabetes Market Size was valued at USD 7.59 billion in 2022 and is expected to reach USD 13.64 billion by 2030, and grow at a CAGR of 7.6% over the forecast period 2023-2030.

People can develop one of two forms of diabetes. Type 1 diabetes now accounts for 10 percent of all diabetes cases worldwide.

Type 1 Diabetes Market Revenue Analysis

Get more information on Type 1 Diabetes Market - Request Free Sample Report

People get this type of diabetes when their bodies don't generate enough insulin or don't produce enough insulin to handle all of the refined and other types of sugars they consume every day! Obese young people are more likely to develop type 1 diabetes. What makes matters worse for people with type 1 diabetes is that they will age quickly. As individuals get older, they tend to embrace unhealthy behaviors. This motivates those with type 1 diabetes to stick with it.



  • Increased acceptance of Western diets

  • lifestyles that promote high-fat eating

  • Less exercise

  • Short - long Term Damage


  • These medications are effective in managing type 1 diabetes

  • They can have unpleasant and even hazardous side effects.


  • Pharmaceutical businesses have benefited from the profitable market.

  • More Development and research in medicines


  • Expensive medication

  • Medicines will face in the near and long term is ensuring that newer generations of drugs are safer.


The year before, COVID-19 proven to be a serious infection. Until early this year, there's no vaccine for it. The virus was contained by governments implementing short quarantines and indefinite lockdowns. Those who did not test positive for COVID-19 suffered the repercussions.

Individuals with other illnesses, including as diabetes and cancer, were unable to receive medical care when they required it since many doctors and other health providers refused to visit patients who did not have life-threatening illnesses. Many persons with Type 1 diabetes were fatally ill or died as a result of this delay.


By Devices

By End-User

  • Hospital

  • Research Institutes

  • Home Care

By Product

  • Rapid-Acting Insulin

  • Short-Acting Insulin

  • Medium-Acting Insulin

  • Long-Acting Insulin

  • Others

Type 1 Diabetes Market Segmentation Analysis

Need any customization research on Type 1 Diabetes Market - Enquiry Now


Corporations and governments in the Asia-Pacific area are stepping in to help diabetics who might otherwise be unable to buy or obtain various treatments.

The European Union has the second-largest market share for type 1 diabetes. This is largely due to the fact that an increasing number of Europeans are moving away from their historically healthy diets and lives and toward less healthy American diets and lifestyles.


North America

  • USA

  • Canada

  • Mexico


  • Germany

  • UK

  • France

  • Italy

  • Spain

  • The Netherlands

  • Rest of Europe


  • Japan

  • South Korea

  • China

  • India

  • Australia

  • Rest of Asia-Pacific

The Middle East & Africa

  • Israel

  • UAE

  • South Africa

  • Rest of Middle East & Africa

Latin America

  • Brazil

  • Argentina

  • Rest of Latin America


The Major Players are Abbott Laboratories, Bayer AG, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd, Merck & C0., Pfizer Inc., Takeda Pharmaceutical, AstraZeneca PLC., XOMA Corp, and others.

Johnson & Johnson Ltd-Company Financial Analysis

Company Landscape Analysis

Type 1 Diabetes Market Report Scope:
Report Attributes Details
Market Size in 2022  US$ 7.59 Billion
Market Size by 2030  US$ 13.64 Billion
CAGR  CAGR of 7.6% From 2023 to 2030
Base Year  2022
Forecast Period  2023-2030
Historical Data  2020-2021
Report Scope & Coverage Market Size, Segments Analysis, Competitive  Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments • By Devices (Insulin Pump, Insulin Pen, Blood Glucose Meter, Others)
• By End-User (Hospital, Research Institutes, Home Care)
• By Product (Rapid-Acting Insulin, Short-Acting Insulin, Medium-Acting Insulin, Long-Acting Insulin, Others)
Regional Analysis/Coverage North America (USA, Canada, Mexico), Europe
(Germany, UK, France, Italy, Spain, Netherlands,
Rest of Europe), Asia-Pacific (Japan, South Korea,
China, India, Australia, Rest of Asia-Pacific), The
Middle East & Africa (Israel, UAE, South Africa,
Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America)
Company Profiles Abbott Laboratories, Bayer AG, Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson Ltd, Merck & C0., Pfizer Inc., Takeda Pharmaceutical, AstraZeneca PLC., XOMA Corp, and others.
DRIVERS • Increased acceptance of Western diets
• lifestyles that promote high-fat eating
• Less exercise
RESTRAINTS • These medications are effective in managing type 1 diabetes
• They can have unpleasant and even hazardous side effects.

Frequently Asked Questions

Ans: The Type 1 Diabetes Market size is estimated to reach US$ 13.64 billion by 2030.

Key drivers of the Type 1 Diabetes Market are the Increased acceptance of Western diets and lifestyles that promote high-fat eating

Januvia, Humalog, Lantus, Novorapid, Galvus, and Humulin are the sub segments by product type.

Top-down, bottom-up, Quantitative, Qualitative Research, Descriptive, Analytical, Applied, and Fundamental Research.

Ans: The Type 1 Diabetes Market is to grow at a CAGR of 7.6% over the forecast period 2023-2030.

Table of Contents

1. Introduction

1.1 Market Definition 

1.2 Scope

1.3 Research Assumptions

2. Research Methodology

3. Market Dynamics

3.1 Drivers

3.2 Restraints

3.3 Opportunities

3.4 Challenges

4. Impact Analysis

4.1 COVID-19 Impact Analysis

4.2 Impact of Ukraine- Russia war

4.3 Impact of ongoing Recession

4.3.1 Introduction

4.3.2 Impact on major economies US Canada Germany France United Kingdom China Japan South Korea Rest of the World

5. Value Chain Analysis


6. Porter’s 5 forces model


7.  PEST Analysis


8. Type 1 Diabetes Market Segmentation, By Devices

8.1. Insulin Pump

8.2. Insulin Pen

8.3. Blood Glucose Meter

8.4. Others

9. Type 1 Diabetes Market Segmentation, By End-User

9.1. Hospital

9.2. Research Institutes

9.3. Home Care

10. Type 1 Diabetes Market Segmentation, By Product

10.1. Rapid-Acting Insulin

10.2. Short-Acting Insulin

10.3. Medium-Acting Insulin

10.4. Long-Acting Insulin

10.5. Others

11. Regional Analysis

11.1 Introduction

11.2 North America

11.2.1 USA

11.2.2 Canada

11.2.3 Mexico

11.3    Europe

11.3.1 Germany

11.3.2 UK

11.3.3 France

11.3.4 Italy

11.3.5 Spain

11.3.6 The Netherlands

11.3.7 Rest of Europe

11.4    Asia-Pacific

11.4.1 Japan

11.4.2 South Korea

11.4.3 China

11.4.4 India

11.4.5 Australia

11.4.6 Rest of Asia-Pacific

1.5    The Middle East & Africa

111.5.1 Israel

11.5.2 UAE

11.5.3 South Africa

11.5.4 Rest

11.6    Latin America

11.6.1 Brazil

11.6.2 Argentina

11.6.3 Rest of Latin America

12. Company Profiles

12.1 Abbott Laboratories

12.1.1 Financial

12.1.2 Products/ Services Offered

12.1.3 SWOT Analysis

12.1.4 The SNS view

12.2 Bayer AG

12.3 Eli Lilly and Company

12.4 GlaxoSmithKline

12.5 Johnson & Johnson Ltd

12.6 Merck & C0.

1.7 Pfizer Inc.

12.8 Takeda Pharmaceutical

12.9 AstraZeneca PLC.

12.10 XOMA Corp

13. Competitive Landscape

13.1 Competitive Benchmark

13.2 Market Share Analysis

13.3 Recent Developments

14. Conclusion

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.


The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data.  This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Start a Conversation

Hi! Click one of our member below to chat on Phone